CO6410297A2 - Tratamiento de trastornos relacionados con la discinesia - Google Patents
Tratamiento de trastornos relacionados con la discinesiaInfo
- Publication number
- CO6410297A2 CO6410297A2 CO11109225A CO11109225A CO6410297A2 CO 6410297 A2 CO6410297 A2 CO 6410297A2 CO 11109225 A CO11109225 A CO 11109225A CO 11109225 A CO11109225 A CO 11109225A CO 6410297 A2 CO6410297 A2 CO 6410297A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- present
- disease
- parkinson
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos de la presente invención contienen dos centros quirales (indicados con * en la fórmula a continuación)Los compuestos de la invención pueden existir en dos formas diastereoméricas diferentes, los isómeros cis- y trans-, los cuales pueden existir en dos formas enatioméricas. La presente invención se relaciona solamente con el racemato trans y el (4aR, 10aR)-enantioméro.Por consiguiente, se espera que los compuestos identificados anteriormente se puedan utilizar para tratar discinesias y otros trastornos relacionados con el movimiento tal como corea de Huntington. Más aún, la presente invención contempla el uso de la mezcla trans racémica correspondiente. La presente invención proporciona adicionalmente métodos para el tratamiento de la enfermedad de Parkinson con un bajo perfil de inducción a discinesia que comprende administrar una cantidad terapéuticamente efectiva de dicho compuesto. En un aspecto, el tratamiento de la enfermedad de Parkinson es tan eficaz como el tratamiento de L-DOPA. Se proporcionan adicionalmente métodos para revertir las discinesias o para tratar la enfermedad de Parkinson que comprenden administrar dicho compuesto y composiciones farmacéuticas del mismo.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15595309P | 2009-02-27 | 2009-02-27 | |
US15596609P | 2009-02-27 | 2009-02-27 | |
US15594309P | 2009-02-27 | 2009-02-27 | |
DKPA200900280 | 2009-02-27 | ||
DKPA200900273 | 2009-02-27 | ||
DKPA200900281 | 2009-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6410297A2 true CO6410297A2 (es) | 2012-03-30 |
Family
ID=42060693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11109225A CO6410297A2 (es) | 2009-02-27 | 2011-08-26 | Tratamiento de trastornos relacionados con la discinesia |
Country Status (20)
Country | Link |
---|---|
US (1) | US20120108624A1 (es) |
EP (2) | EP2400967B1 (es) |
JP (1) | JP5738775B2 (es) |
KR (1) | KR101700978B1 (es) |
CN (1) | CN102333531B (es) |
AR (1) | AR075625A1 (es) |
AU (1) | AU2010217059B2 (es) |
BR (1) | BRPI1007017A2 (es) |
CA (1) | CA2751322C (es) |
CL (1) | CL2011002102A1 (es) |
CO (1) | CO6410297A2 (es) |
EA (1) | EA023778B1 (es) |
HK (1) | HK1166472A1 (es) |
IL (1) | IL213502A (es) |
MX (1) | MX340138B (es) |
NZ (1) | NZ594264A (es) |
SG (1) | SG174163A1 (es) |
TW (1) | TW201036949A (es) |
WO (1) | WO2010097092A1 (es) |
ZA (1) | ZA201106294B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10729710B2 (en) * | 2017-11-24 | 2020-08-04 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's disease |
WO2020070099A1 (en) | 2018-10-02 | 2020-04-09 | H. Lundbeck A/S | Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist |
US11168056B2 (en) * | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US11104697B2 (en) * | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
US11111263B2 (en) * | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
EP3972600A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
WO2020234274A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
CN113727974A (zh) * | 2019-05-21 | 2021-11-30 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
US20220213136A1 (en) | 2019-05-21 | 2022-07-07 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
CN116568672A (zh) | 2020-11-17 | 2023-08-08 | H.隆德贝克有限公司 | 用于治疗帕金森病的新儿茶酚胺前药 |
WO2023208869A1 (en) | 2022-04-25 | 2023-11-02 | Integrative Research Laboratories Sweden Ab | NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
WO2023208865A1 (en) | 2022-04-25 | 2023-11-02 | Integrative Research Laboratories Sweden Ab | NOVEL 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
WO2023208867A1 (en) | 2022-04-25 | 2023-11-02 | Integrative Research Laboratories Sweden Ab | NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0001438D0 (sv) * | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
TWI404702B (zh) * | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
-
2010
- 2010-02-25 TW TW099105396A patent/TW201036949A/zh unknown
- 2010-02-26 WO PCT/DK2010/050051 patent/WO2010097092A1/en active Application Filing
- 2010-02-26 MX MX2011008944A patent/MX340138B/es active IP Right Grant
- 2010-02-26 AU AU2010217059A patent/AU2010217059B2/en active Active
- 2010-02-26 NZ NZ594264A patent/NZ594264A/xx not_active IP Right Cessation
- 2010-02-26 SG SG2011061785A patent/SG174163A1/en unknown
- 2010-02-26 JP JP2011551409A patent/JP5738775B2/ja not_active Expired - Fee Related
- 2010-02-26 CA CA2751322A patent/CA2751322C/en active Active
- 2010-02-26 CN CN2010800098743A patent/CN102333531B/zh active Active
- 2010-02-26 EP EP10707436.1A patent/EP2400967B1/en active Active
- 2010-02-26 EP EP19191241.9A patent/EP3653210A1/en active Pending
- 2010-02-26 EA EA201171088A patent/EA023778B1/ru not_active IP Right Cessation
- 2010-02-26 US US13/202,768 patent/US20120108624A1/en not_active Abandoned
- 2010-02-26 BR BRPI1007017A patent/BRPI1007017A2/pt not_active Application Discontinuation
- 2010-02-26 KR KR1020117019748A patent/KR101700978B1/ko active IP Right Grant
- 2010-02-26 AR ARP100100573A patent/AR075625A1/es unknown
-
2011
- 2011-06-12 IL IL213502A patent/IL213502A/en active IP Right Grant
- 2011-08-26 CO CO11109225A patent/CO6410297A2/es not_active Application Discontinuation
- 2011-08-26 CL CL2011002102A patent/CL2011002102A1/es unknown
- 2011-08-26 ZA ZA2011/06294A patent/ZA201106294B/en unknown
-
2012
- 2012-07-23 HK HK12107220.3A patent/HK1166472A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2400967B1 (en) | 2019-08-14 |
JP2012519157A (ja) | 2012-08-23 |
KR101700978B1 (ko) | 2017-01-31 |
IL213502A (en) | 2017-02-28 |
CN102333531B (zh) | 2013-11-06 |
CA2751322A1 (en) | 2010-09-02 |
CN102333531A (zh) | 2012-01-25 |
CL2011002102A1 (es) | 2012-07-20 |
JP5738775B2 (ja) | 2015-06-24 |
CA2751322C (en) | 2017-10-31 |
AU2010217059B2 (en) | 2012-08-30 |
AU2010217059A1 (en) | 2011-08-11 |
WO2010097092A1 (en) | 2010-09-02 |
US20120108624A1 (en) | 2012-05-03 |
EA201171088A1 (ru) | 2012-02-28 |
HK1166472A1 (en) | 2012-11-02 |
EP2400967A1 (en) | 2012-01-04 |
TW201036949A (en) | 2010-10-16 |
IL213502A0 (en) | 2011-07-31 |
NZ594264A (en) | 2013-11-29 |
BRPI1007017A2 (pt) | 2016-03-29 |
EP3653210A1 (en) | 2020-05-20 |
MX2011008944A (es) | 2011-09-15 |
AR075625A1 (es) | 2011-04-20 |
ZA201106294B (en) | 2012-10-31 |
EA023778B1 (ru) | 2016-07-29 |
MX340138B (es) | 2016-06-28 |
SG174163A1 (en) | 2011-10-28 |
KR20110132340A (ko) | 2011-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6410297A2 (es) | Tratamiento de trastornos relacionados con la discinesia | |
CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
CL2017003138A1 (es) | Compuesto derivado triciclico, metodo de preparacion del mismo y composicion farmaceutica que lo comprende. | |
UY32456A (es) | Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento | |
UY31384A1 (es) | Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b | |
CR20180339A (es) | INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576) | |
UY33480A (es) | Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento. | |
CR11627A (es) | Derivados heterociclicos fusionados y metodos de uso como inhibidores c-met | |
CR10868A (es) | Derivados de dihidropiridina utiles como inhibidores de la proteina quinasa | |
CL2014000314A1 (es) | Compuestos derivados de ciclopropanamina, inhibidores de desmetilasa especifica de lisina 1 (lsd1); medicamento que los comprende; metodo para profilaxis o tratamiento; metodo para inhibir lsd1; y su uso en la profilaxis o tratamiento de esquizofrenia, enfermedad de alzheimer, enfermedad de parkinson o corea de huntington. | |
UY30986A1 (es) | Derivados fluorinados de deferiprona | |
EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
EA201491335A1 (ru) | Бигуанидные композиции и способы лечения метаболических расстройств | |
EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
EA201101190A1 (ru) | Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение | |
GT200800138A (es) | Combinacion de un inhibidor de acetilcolinesterasa y un agonista de 5-ht6 para el tratamiento de disfuncion cognitiva | |
ES2560676T3 (es) | Combinación farmacéutica para el tratamiento del dolor | |
BR112015011147A8 (pt) | composto, composição farmacêutica, e, uso do referido composto | |
BR112015011148A2 (pt) | composto, composição farmacêutica, e, métodos para tratar uma doença e uma condição | |
CO6382089A2 (es) | Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias | |
EA201100921A1 (ru) | Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ | |
BR112015008717A2 (pt) | composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii | |
CO6630193A2 (es) | Inhibidores de la actividad de la proteína tirosina quinasa seleccionada | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
EA201001586A1 (ru) | Соединения и композиции в качестве ингибиторов itpkb |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |